Introduction {#Sec1}
============

Humankind has previously witnessed the outbreak of many life-threatening pathogens including Ebola, Zika, the Middle East respiratory syndrome (MERS) coronavirus, severe acute respiratory syndrome (SARS) coronavirus and, nowadays, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Memish et al. [@CR21]; Organization; Sikka et al. [@CR30]; Stawicki et al. [@CR30]; Su et al. [@CR31]; Xiong et al. [@CR36]). The novel coronavirus has initially spread from China and propagated rapidly throughout the globe and has received worldwide attention due to its alarming levels of transmission and aggressive behavior in causing acute respiratory disease. The virus was then officially declared pandemic as a public health emergency of international concern by the World Health Organization (WHO). Researchers throughout the globe are working around the clock to develop potential vaccines and drugs to fight the new coronavirus, SARS-CoV-2, the causative agent of the COVID-19 disease. However, developing a new drug or vaccine usually takes a long time as it should be intensively tested and confirmed to be safe through clinical trials before they can be approved for human use (Control and Prevention [@CR9]; GSK files for approval of world's first malaria vaccine [@CR14]). Therefore, repurposing FDA-approved drugs seems to be a quicker way to treat patients who otherwise have no option. The SARS-CoV-2 is a single-stranded positive-sense RNA virus that relies on its spike (S) protein to attach and enter the target cells (Chiang [@CR7]; Hoffmann et al. [@CR15]; Wu et al. [@CR35]). The virus S protein binds to the host cell angiotensin-converting enzyme 2 (ACE2) receptor, allowing the virus particles to enter the cells (Chiang [@CR7]; Hoffmann et al. [@CR15]; Wan et al. [@CR34]). Thus, blocking the ACE2 receptor reveals a potential therapeutic target for drug discovery to prevent SARS-CoV-2 transmissibility. Besides, two coronavirus proteases, designated 3-chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro), were previously considered vital targets to combat the SARS and MERS coronavirus epidemics (Wu et al. [@CR35]). These two proteases were shown to be highly conserved with the novel SARS-CoV-2, especially in the functional regions (Wu et al. [@CR35]). Viruses use their proteases to break down their viral peptides into functional units essential for replication and packaging inside the host cells, and thus considered antiviral drug targets. Molecular docking is a popular bioinformatic modeling tool broadly used in structure-based drug design (Kitchen et al. [@CR17]; Mubarak et al. [@CR22]; Naik [@CR23]; Naik and Pardasani [@CR24], [@CR25]; Naik and Zu [@CR26]). It is an efficient way to predict the type of interaction, binding affinity and the appropriate target-binding sites between the drug and corresponding receptor using, for instance, scoring functions (Kitchen et al. [@CR17]; Lengauer and Rarey [@CR19]). Elucidating the binding behavior plays an important role in the rational design of drugs as well as to explicate fundamental biochemical processes (Kitchen et al. [@CR17]; Lengauer and Rarey [@CR19]). In this study, molecular docking was performed on dozens of FDA-approved drugs and the top ten hits, previously used in the treatment of malarial, fungal/bacterial and Ebola infections and FDA-approved/fast-tracked for human treatment, were selected. For the selected drugs used in this study, the MOE modeling program was used to predict the binding sites and their docking score.

Materials and methods {#Sec2}
=====================

Molecular docking method {#Sec3}
------------------------

### Software and machinery used {#Sec4}

All docking studies were performed and characterized by the MOE \"Molecular Operating Environment\" program. Drug preparation was compiled through ChemDraw, 3D structures were constructed using Chem 3D ultra 12.0 software (Molecular Modeling and Analysis; Cambridge Soft Corporation), then they were energetically minimized using MOPAC and saved as MDL MolFile (\*.mol). All calculations were carried out on an Intel(R) Core(TM)i7, 3.8 GHz-based machine running MS Windows 10 as the operating system(Mubarak et al. [@CR22]; Naik [@CR23]; Naik and Pardasani [@CR24], [@CR25]; Naik and Zu [@CR26]).

### SARS-CoV-2 protease and receptor structure {#Sec5}

Generation of the protein structures and the crystal structure of the new COVID-19 protease (PDB code = 1Q2W) and ACE2 receptor (PDB code = 6M0J) were retrieved from the Protein Data Bank (<http://www.rcsb.org/pdb/welcome.do>) (Bonanno et al. [@CR5]). All bound waters, ligands and cofactors were removed from the proteins and then we added hydrogen atoms for optimization.

### Molecular docking procedure {#Sec6}

The docking protocol was done against the SARS-CoV-2 ACE2 receptor (PDB code = 6M0J), the SARS-CoV-2 3CL protease (PDB code = 1Q2W) and its four active sites. The active sites were isolated and used as dummy atoms. The parameters and charges were assigned with the MMFF94x force field. After alpha-site spheres were generated using the site finder module of MOE, the structural model of the compounds were docked on the surface of the interior of the receptor using the DOCK module of MOE (Abdel-Rhman et al. [@CR2]). The Dock scoring in MOE software was done through the London dG scoring function and has been upgraded by two unrelated refinement methods. Auto rotatable bonds were allowed, and the best five binding poses were directed for analysis to achieve the best score. We used the database browsers to compare the docking poses to the ligand in the co-crystallized structure and to obtain RMSD of the docking pose. To rank the binding affinity of the synthesized compounds to the protein molecule, the binding free energy and hydrogen bonds between the compounds and amino acid in the receptor were calculated (Abdellattif et al. [@CR1]; Ketan et al. ([@CR32]). Evaluation of the hydrogen bonds was done by measuring the hydrogen bond length, which does not exceed 3.5 A°. Also, the RMSD of the drug position compared to the docking pose was used in the ranking. RMSD, as well as the mode of interaction of the native ligand within the structure of the receptor, was used as a standard docked model (Abdel-Rhman et al. [@CR2]; Abdellattif et al. [@CR1]; Althagafi et al. [@CR3]; Mashat et al. [@CR20]; Ketan et al. [@CR32]).

Results and discussions {#Sec7}
=======================

Molecular docking and other computer-related methods are efficient tools broadly used to understand the molecular aspects of protein--ligand interactions during drug discovery against many of previous emerging and fatal diseases including SARS coronavirus (Kitchen et al. [@CR17]; Lengauer and Rarey [@CR19]). In this study, virtual screening of several FDA-approved/fast-tracked drugs was performed against the SARS-CoV-2 ACE2 host receptor (PDB code = 6M0J), the SARS-CoV-2 3CL protease (PDB code = 1Q2W) and its four active sites, to find the most predicated drug--ligand interactions. The presented parameters include the docking scores, ligand binding efficiency and hydrogen bonding interactions. The top ten ranked compounds were selected and are presented in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"} and Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}. These ten drugs include four antivirals (*favipiravir, ribavirin, brincidofovir, and galidesivir*), four antimalarial (*chloroquine, mefloquine, primaquine, and tafenoquine*) and two antimicrobial agents (*doxycycline and atovaquone*). Whether we docked against the ACE2 receptor (PDB code = 6M0J), the SARS-CoV-2 3CL protease (PDB code = 1Q2W) or the four main active sites within the SARS-CoV-2 3CL protease, the docking scores of)*brincidofovir* or BCV) were shown to be the top hit (ranked \#1) compared to the other nine drugs. The docking scores for the BCV were − 10.83, − 8.30 and − 9.02 toward the SARS-CoV-2 3CL protease active site 1 (PDB code = 1Q2W), the SARS-CoV-2 3CL whole protease (PDB code = 1Q2W) (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} and Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}) and the ACE2 receptor (PDB code = 6M0J) (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} and Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}), respectively. The antimalarial drug *tafenoquine* comes second in the rank where it scored − 8.15 and − 7.76 with the AC2 receptor and the SARS-CoV-2 3CL protease active site 1, respectively (Tables [2](#Tab2){ref-type="table"} and [4](#Tab4){ref-type="table"}). Table 1Docking score and energy of the malaria and Ebola drugs and 1Q2W of COVID-19 with site 1 of COVID-19 protease (PDB code = 1Q2W)Table 2Interaction between malaria and Ebola drugs and 1Q2W of COVID-19 with site 1 of COVID-19 protease (PDB code = 1Q2W)Drug nameLigandReceptorInteractionDistanceE (kcal/mol)Atovaquone6-ringCD PRO 122 (B)pi-H4.11− 0.5ChloroquineO 5NZ LYS 5 (A)H-acceptor3.34− 0.96-ringCB LYS 137 (A)pi-H4.16− 0.66-ringCA GLY 2 (B)pi-H3.49− 0.5DoxycyclineN 6N GLN 127 (A)H-acceptor3.27− 3.2MefloquineO 41OG1 THR 285 (A)H-donor3.09− 0.9PrimaquineF 1N GLN 127 (B)H-acceptor3.05− 0.66-ringCG LYS 5 (B)pi-H3.72− 0.8TafenoquineN 27NH1 ARG 4 (B)H-acceptor3.58− 1.66-ringCD LYS 5 (A)pi-H4.49− 0.7FavipiravirN 13O LYS 5 (A)H-donor3.16− 1.6N 9N GLN 127 (B)H-acceptor3.32− 2.3RibavirinO 1O PHE 3 (B)H-donor2.98− 0.8O 15NZ LYS 5 (A)H-acceptor3.26− 1.2O 26N GLN 127 (B)H-acceptor3.14− 3.2N 27N GLN 127 (A)H-acceptor3.32− 2.15-ringCB LYS 5 (B)pi-H3.99− 0.7GalidesivirO 33O PHE 3 (B)H-donor3.00− 1.2N 9NH1 ARG 4 (B)H-acceptor3.25− 4.0N 12N GLN 127 (A)H-acceptor3.59− 1.06-ringCD LYS 5 (A)pi-H4.39− 0.7BrincidovirO 63O GLN 127 (B)H-donor3.02− 2.9O 68NH1 ARG 4 (A)H-acceptor2.95− 2.4Table 3Docking score and energy of the malaria and Ebola drugs with ACE-2 receptor (PDB code = 6M0J)Table 4Interaction between malaria and Ebola drugs with ACE-2 receptor (PDB code = 6M0J)DrugLigandReceptorInteractionDistanceE (kcal/mol)Atovaquone6-ringCA VAL 209 (A)pi-H3.90− 1.0ChloroquineN 17O GLU 208 (A)H-donor3.16− 0.6CL 1NZ LYS 94 (A)H-acceptor3.45− 0.96-ringCA VAL 209 (A)pi-H4.40− 0.56-ringCG1 VAL 209 (A)pi-H4.14− 0.66-ringN ASN 210 (A)pi-H3.62− 0.6DoxycyclineO 24OE1 GLU 208 (A)H-donor3.01− 1.86-ringCG2 VAL 209 (A)pi-H4.28− 0.7MefloquineN 29O ASN 210 (A)H-donor2.91− 0.7N 29N ASN 210 (A)H-acceptor3.33− 0.56-ringCB GLU 208 (A)pi-H4.42− 0.56-ringCG2 VAL 209 (A)pi-H4.46− 0.6Primaquine6-ringCG1 VAL 209 (A)pi-H4.24− 0.76-ringCG1 VAL 209 (A)pi-H4.52− 0.7TafenoquineNo measured interactionFavipiravirO 12NZ LYS 94 (A)H-acceptor3.12− 3.5RibavirinO 15NZ LYS 562 (A)H-acceptor3.03− 3.6GalidesivirN 14O ASN 210 (A)H-donor3.05− 1.0O 29CE LYS 562 (A)H-acceptor3.16− 0.75-ringCA VAL 209 (A)pi-H3.79− 2.16-ringCA VAL 209 (A)pi-H4.40− 0.55-ringN ASN 210 (A)pi-H4.25− 2.76-ringND2 ASN 210 (A)pi-H4.58− 1.3BrincidovirO 63OE2 GLU 208 (A)H-donor2.79− 6.4O 74NE2 GLN 98 (A)H-acceptor3.01− 1.2Table 5Docking score and energy of ivermectin drug and 1Q2W of COVID-19 with site 1 of COVID-19 protease (PDB code = 1Q2W)Table 6Docking score and energy of ivermectin drug with ACE-2 receptor (PDB code = 6M0J)Fig. 13d Docking of malaria and Ebola drugs and 1Q2W of COVID-19 with site 1 of COVID-19 protease (PDB code = 1Q2W)Fig. 22d Docking of malaria and Ebola drugs and 1Q2W of COVID-19 with fixing the active site 1 of of COVID-19 protease (PDB code = 1Q2W)Fig. 33d Docking of malaria and Ebola drugs with ACE-2 receptor (PDB code = 6M0J)Fig. 42d Docking of malaria and Ebola drugs with ACE-2 RECEPTOR (PDB CODE = 6M0J)Fig. 5Chemical structure of ivermectin

Brincidofovir (BCV) is an orally bioavailable, long-acting nucleotide analog broad-spectrum antiviral developed by Chimerix Inc. of Durham, North Carolina, USA, for the treatment of double-stranded DNA (dsDNA) viruses (Lanier et al. [@CR18]). BCV is less toxic with an enhanced cellular penetration prodrug of cidofovir, wherein the cidofovir acyclic nucleoside monophosphate is conjugated through its phosphonate group to a lipid, 3-(hexadecyloxy)-1-propanol (Florescu and Keck [@CR11]). Being linked to a lipid particle, the compound ensures better and higher intracellular releases of cidofovir and lower plasma concentrations of the active drug, effectively increasing its antiviral activity. When intracellular, the released free cidofovir from the BCV is phosphorylated to its active metabolite cidofovir diphosphate, which, due to its structural similarity to the deoxycytidine triphosphate (dCTP) nucleotides, gets incorporated into the growing viral DNA strands (Parker et al. [@CR28], [@CR29]). Once incorporated, it prevents further DNA polymerization and disrupts DNA replication of viruses. The drug received FDA Fast Track Designation and has been evaluated in healthy individuals in Phase I studies and in hematopoietic cell transplant recipients and other immunocompromised patients in Phase II/III clinical trials and revealed to be well tolerated and highly efficacious against adenoviruses, BK virus, herpes simplex viruses, and smallpox, but eventually somehow failed for cytomegalovirus (Chittick et al. [@CR8]; Hoiberg and Rapaka [@CR16]; Schepers). Preliminary in vitro tests have also shown the drug potential for the treatment of Ebola virus disease, despite that Ebola is an RNA virus, albeit trials were eventually discontinued (Dunning et al. [@CR10]). Being acted on the Ebola RNA virus so, it is encouraging to act as well on the novel RNA SARS-CoV-2. In addition to its intracellular therapeutic strategy of arresting viral replication and packaging, our study shows here that it also interferes efficiently with the SARS-CoV-2 ACE2 receptor, revealing a different therapeutic mode of action through potentially blocking or inhibiting the virus entry to the host cell, thereby slowing the progression of the infection.

The second top-ranked drug is *tafenoquine* which is an orally active 8-aminoquinoline, a long-acting analog of primaquine, antimalarial medicine developed by GlaxoSmithKline and 60 Degrees Pharmaceuticals (Baird [@CR4]; Frampton [@CR12]). The drug was FDA approved for the radical cure of *Plasmodium vivax* (*P. vivax*) malaria and the prophylaxis of malaria in 2018. The drug is active against pre-erythrocytic, erythrocytic forms and the gametocytes of Plasmodium species that include *P. falciparum* and *P. vivax* (Baird [@CR4]; Frampton [@CR12]). Clinical trials for this drug may be also recommended. Chloroquine, which is an antimalaria and immunosuppressive drug, has been recently shown to improve the outcomes in patients with the novel coronavirus pneumonia, which made the FDA issue an Emergency Use Authorization to be tested as a treatment for COVID-19, ranked at the fourth position in this study (Gao et al. [@CR13]).

Lastly, while we were working in this research, an Australian study showed that *ivermectin*, an antiparasitic drug, was effective against COVID-19 disease, although further clinical trials are underway to confirm this effectiveness (Caly et al. [@CR6]). We decided to do some investigations using molecular docking to check the binding interaction between ivermectin and the SARS-CoV-2 protease and receptor. We got comparable data to the antiviral *Brincidofovir* where the docking scores were -10.31 and -8.84 with the SARS-CoV-2 protease and ACE2 receptor (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}), respectively. But overall, brincidofovir is better recommended because for its high lipophilicity "5.54", whereas for ivermectin it is "2.01".

In conclusion, molecular modeling tools were used to screen for potential anti-SARS-CoV-2 therapeutic agents. After a virtual screening against SARS-CoV-2 protease and ACE2 receptor, a set of antivirals, antimalarials, and antimicrobials drugs showed a potent binding interaction, wherein biocidofovir was the top hit. Therefore, repurposing of biocidofovir against COVID-19 disease is suggested for clinical trials.
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